Testosterone + hCG: How This Combination Preserves Fertility on TRT

Testosterone replacement therapy is effective at correcting the symptoms of low testosterone, but it has a well-documented side effect that has nothing to do with how someone feels day to day: it suppresses the body's own reproductive signaling, which can reduce or eliminate natural fertility. Human chorionic gonadotropin (hCG) is the most established way protocols address that specific side effect. Here's the actual mechanism, and what published outcome data shows.

Why TRT shuts down natural production in the first place

Testosterone production in the body isn't a one-way process — it's controlled by a feedback loop called the hypothalamic-pituitary-gonadal (HPG) axis. The hypothalamus releases gonadotropin-releasing hormone (GnRH), which signals the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH is what actually reaches the testes and stimulates the Leydig cells to produce testosterone.

That loop has a built-in brake: when the brain detects that testosterone levels are already high, it reduces GnRH release, which reduces LH and FSH, which reduces the testes' own production. This mechanism doesn't distinguish between testosterone the body made and testosterone that arrived by injection or gel — the hypothalamus responds to circulating testosterone level, not its source. GnRH neurons themselves don't have androgen receptors; the actual sensing happens via testosterone acting on androgen-receptor-expressing kisspeptin neurons in the hypothalamus, which then dial back pulsatile GnRH release.

The practical timeline is fast: LH and FSH typically decline within days of starting exogenous testosterone, natural production is noticeably reduced within one to two weeks, and near-complete suppression is common by the two-to-four week mark. Because LH is what actually drives testicular testosterone production and supports spermatogenesis, its suppression is what causes the fertility impact — not the exogenous testosterone itself acting directly on the testes.

What hCG actually does differently

hCG works around this problem rather than reversing it. Structurally, hCG binds the same receptor LH does — the LH/choriogonadotropin receptor (LH/CGR) on Leydig cells — and triggers the same downstream steroidogenesis. The difference is where the signal comes from: hCG is administered directly, so it stimulates the testes regardless of what the suppressed pituitary is or isn't releasing. In effect, it substitutes for the missing LH signal rather than trying to restart the brain's own production of it.

hCG also behaves differently in the body than LH does. Its beta-subunit carries a heavily glycosylated tail that LH's does not, which increases receptor activity and substantially slows its clearance — published pharmacokinetic data puts hCG's half-life at roughly 36 hours, compared to about 30 minutes for endogenous LH. That longer half-life is part of why hCG is a practical substitute for a hormone that's normally released in short pulses: a much longer-acting molecule can maintain steadier receptor stimulation between doses than the natural pulse pattern would otherwise require.

What the published outcome data actually shows

A 2015 case series in the Journal of Sexual Medicine (Wenker, Dupree, and colleagues) followed 49 men with testosterone-related azoospermia or severe oligospermia who were started on hCG-based combination therapy. Spermatogenesis was restored in 47 of 49 men — 95.9% — with a mean time to recovery of 4.6 months.

More recent research adds an important detail: a 2025 study from Baylor College of Medicine found that 74% of men with TRT-related infertility showed improved sperm concentrations on hCG/FSH combination therapy, and that improvement occurred at similar rates whether men continued TRT during treatment or stopped it — suggesting the benefit comes specifically from restoring the testicular signal, not simply from removing exogenous testosterone.

A single dose doesn't act all at once

Testicular steroidogenesis doesn't respond to hCG as a single, immediate spike. Direct measurement of steroid levels in spermatic and peripheral vein blood after hCG administration has shown a genuinely two-phase response: a rapid initial rise in testicular steroid output within hours, followed by a second, larger and slower rise over the following day or so. That biphasic pattern is part of why hCG protocols are typically built around a dosing interval rather than a single injection — the testicular response to any one dose unfolds over roughly a day, not minutes, which is also consistent with hCG's own multi-day clearance.

This also explains why hCG is not simply "instant LH." Even though it binds the identical receptor, the actual steroidogenic output it produces plays out on its own timeline, shaped by both the receptor-level pharmacodynamics and hCG's comparatively long circulating half-life. A protocol built around this compound is working with that timeline, not against it.

Why this is a tracking problem as much as a pharmacology one

The entire premise of this combination is maintaining a steady replacement signal to the testes while the body's own signal stays suppressed. That only works if the hCG side of the protocol is actually administered on a real, known schedule — not "roughly twice a week, whenever it comes to mind." hCG's ~36-hour half-life is more forgiving of small timing variance than a hormone with a half-life measured in minutes, but a gap that's significantly longer than intended still means a real stretch of time with reduced testicular stimulation, on top of whatever the TRT side of the protocol is doing. Two compounds, run on two different schedules, aimed at two different physiological targets, is exactly the kind of protocol that's hard to hold in memory accurately over months — which is the actual, practical case for keeping a real log instead of trusting recall.